EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Platform · Ingredient Engine

Each stage has to earn the next

The Ingredient Engine is EUTECNIQ’s proposed development system: eight stages from candidate selection and sourcing to a commercial route. Regulatory and economic feasibility is screened at intake and screened again whenever the material, process, formulation or intended use changes.

The engine shows how EUTECNIQ would decide: which technology to use, which alternatives fail, what evidence is missing and when to stop.

Proposed capabilityCompany in formation (what exists today). Every stage here is a proposal; rules and published evidence are cited in each stage.

The engine at a glance

8
stages, from candidate to commercial route
1
feasibility screen, run at intake and again on every change of material, process, formulation or intended use
3
outcomes at every gate: progress, repeat or stop
4
routes to value: a client program, a license, supply or a partnered drug program

Part of the Large Botanical Model. The Engine describes how a development program would run; the models that would guide each stage are the Large Botanical Model. See the platform, its status and roadmap.

01 · The engine

Every stage ends in a decision to progress, repeat or stop

One workspace: the eight stages, with one worked program running on them. Change a decision of the turmeric-extract program, and the diagram marks which stages stay settled, reopen or reject it. Select a stage to see that program’s decision, the alternatives turned down, the physical and commercial consequence and the evidence still missing, above the stage’s general method. The band above the stages is the feasibility screen, which runs again whenever the material, process, formulation or intended use changes.

  1. 0Intake and screen
  2. 1Discover and prioritize
  3. 2Authenticate the source
  4. 3Extract and optimize
  5. 4Characterize and standardize
  6. 5Engineer delivery
  7. 6Safety and performance
  8. 7Scale and transfer
  9. 8Commercialize
The Ingredient Engine: eight stages under one feasibility screenEducational schematic of the proposed Ingredient Engine. A band across the top is the regulatory and economic feasibility screen; it starts at project intake and is connected by re-screen loops to stage 2 (material change), stage 3 (process change), stage 5 (formulation change), stage 6 (intended-use change), stage 7 (process change) and stage 8 (intended-use change). Below it, a progress line runs from intake through eight numbered stages, with a gate between each pair where the program proceeds, repeats or stops. Five example repeat loops run back: from 3 to 2 to requalify the source, from 4 to 3 to re-optimize, from 6 to 5 to reformulate, from 7 to 3 when attributes drift at scale, and from 8 to 6 when a claim needs more evidence. Under each stage is the document it produces: screen record; candidate dossier and draft target profile; identity passport and supplier file; process description and mass balance; specification and validated methods; prototype and delivery dossier; safety and exposure assessment; transfer package and control strategy. Stage 8 leaves by four routes: a client program, a license, supply, or a partnered drug program.Regulatory and economicfeasibility screenMaterialProcessFormulationIntended useProcessIntended useRequalify sourceRe-optimizeReformulateDrift at scale: redesign processClaim needs more evidenceRepeatloopsScreenrecord1Candidatedossier, drafttarget profile2Identitypassport,supplier file3Processdescription,mass balance4Specification,validatedmethods5Prototype,delivery dossier6Safety andexposureassessment7Transferpackage, controlstrategy8Client programLicenseSupplyPartnered drugprogram
  • Progress through a gate
  • Repeat an earlier stage
  • Re-screen after a change
  • Document produced
Educational schematic Proposed capability The Ingredient Engine as proposed: eight stages, the gate between each pair, five typical repeat loops and the feasibility screen that runs at intake and re-runs after changes. The loops are examples; any gate can stop a program, and the record is kept. Rules and sources for each stage are in its detail view.

Proposed capability Eight proposed stages. The dashed rail is the feasibility screen: it starts at intake, and a marked stage sends the program back to it when that stage changes the material, process, formulation or intended use. Select a stage to open its detail.

0Intake and the regulatory and economic feasibility screen

Is there a lawful route for the intended use, and can its evidence be produced at a cost the product can carry?

Proceeds when A lawful route exists for the intended use, and its evidence can be produced at an acceptable cost.Produces A dated screen record that every later gate reads and amends

The problem it solves

Intended use decides the U.S. category: dietary supplement, food, cosmetic or drug. The category fixes the safety standard, the evidence worth producing and the document that closes the work. Found late, the answer can leave finished work in the wrong category or priced out of its market.

What is screened

  • Regulatory. The category implied by the intended use and claims; whether the ingredient is a new dietary ingredient, which needs a notification at least 75 days before marketing unless the food-supply exception applies; conservation, import and access rules; the drug path where a therapeutic signal exists.
  • Economic. The cost of the evidence the route needs, the process cost drivers and the margin the market would support.

How alternatives are selected

The route chosen is the one whose evidence can be produced at an acceptable cost. Stop criteria are written before the work starts. Counsel reviews any conclusion that is a legal question.

What is recorded

Intended use and target markets, the category hypothesis and route, the evidence list with a cost range, and the stop criteria.

What it produces

A dated feasibility screen record. FDA does not approve dietary supplements or NDI notifications, so the record states the route and its document, never an approval.

Commercial value

It is the cheapest decision in the program, and it guards against the most expensive mistake: finishing development in a category the product cannot lawfully enter. Evidence costs are large enough to decide a program. In EU contract-laboratory quotes from 2010 to 2018, one carcinogenicity study cost about €700,000.

Published evidence What each kind of change sends back to the screen. Rules as of October 2026; not legal advice.

Changes that re-run the feasibility screen, the stages where they usually arise, what is re-checked and the rule or source
ChangeUsually atRe-checkedRule or source
Material: species, plant part, origin or supplierStage 2Identity and new-dietary-ingredient status; conservation and access terms; contaminant profile; supply cost and securityIdentity in an NDI notification starts with the Latin binomial name, including the author (21 CFR 190.6(b)(2)); CITES; Nagoya Protocol
Process: solvent, concentration or purification step, scale or siteStages 3 and 7Whether the extract is still the same ingredient; residual-solvent class; comparability with earlier lots; cost of goodsWhen a notification is required, including what “chemically altered” means, is still addressed only in FDA’s 2016 revised draft guidance (FDA 2016); ICH Q3C(R9); comparability logic of ICH Q5E
Formulation: carrier, particle size or dosage formStage 5The safety case for the new form; the excipients’ status in the category; whether the form stays in the category; the cost of new studiesFor a nanoscale form, FDA states that data on the conventional form alone are unlikely to address its safety (FDA NDI guidance, October 2026); sublingual products “are not dietary supplements and are not foods” (FDA warning letter, February 5, 2019)
Intended use: claims, population, dose or marketStages 6 and 8The category; the studies needed; whether a drug path opens; the cost of the new evidenceArticles intended to diagnose, cure, mitigate, treat or prevent disease are drugs (21 U.S.C. 321(g)(1)); structure/function statements (21 CFR 101.93); reproductive and developmental data recommended when a product is intended for use in pregnancy, lactation or young children (FDA NDI guidance); an IND for studies of disease endpoints (21 CFR Part 312)

Progress when

A lawful route exists for the intended use, and its evidence can be produced at an acceptable cost.

Repeat when

The material, process, formulation or intended use changes at any later stage (table above).

Stop when

The intended use falls outside every lawful channel, or the evidence would cost more than the commercial case can carry.

Sources: 21 U.S.C. 321; 21 CFR 190.6; FDA NDI guidance (October 2026); Meigs et al., ALTEX 2018, Table 3 (third-party estimate; EU prices, probably below 2026 levels). Stop criteria and the screen record are EUTECNIQ proposals.

1Discover and prioritize

Which candidates deserve laboratory time, and on what evidence?

Proceeds when The candidate has documented starting evidence, a category hypothesis and a source that can be qualified.Produces Candidate dossier, active-constituent map, draft target product profile

The problem it solves

Candidates are many; plant material, instrument time and money are scarce. Kew counted 25,791 documented medicinal plant species in 2020, and of 5,411 assessed for extinction risk, 723 (13%) were threatened. Most candidates have to be dropped before the bench, and sourcing is screened from the start.

Technologies evaluated

  • Literature, database and traditional-use review; traditional use is one possible starting evidence and is not clinical proof
  • Computed molecular descriptors checked against published rules, such as Lipinski’s rule of five
  • Bioactivity-guided fractionation, with dereplication to drop known compounds early
  • LC-HRMS and molecular networking of MS/MS spectra (GNPS)

How alternatives are selected

Candidates are ranked on their starting evidence, the intended use and its category, whether a lawful and sustainable source exists, and a first estimate of the evidence cost. A model may rank candidates; its ranking would inform a decision only after its error has been measured on botanicals it never saw.

What is measured

Where a program traces its actives: the activity of each fraction, and accurate mass and fragments of the active constituents. For every candidate: the access and conservation status of the source. Computed properties are recorded as predictions.

What it produces

A candidate dossier with sources and access status, an active-constituent map with draft markers, and a draft target product profile: intended use, category, format and the claims the evidence would have to support.

Commercial value

Stopping a weak candidate while the answer costs a literature search, instead of a pilot campaign, is the cheapest saving in the program. The dossier is the basis of a scoped development proposal.

Progress when

The candidate has documented starting evidence, a category hypothesis and a source that can be qualified.

Repeat when

New evidence, or a changed intended use, re-ranks the list.

Stop when

There is no documented starting evidence, the species is threatened without a sustainable source, access terms cannot be agreed, or activity disappears on fractionation or traces to a known toxicant.

Sources: Royal Botanic Gardens, Kew 2020; Lipinski et al. 2001; Wang et al. 2016 (GNPS). Ranking criteria are EUTECNIQ proposals.

2Authenticate and qualify the source

Is the material what the supplier says it is, and can it be supplied consistently and lawfully?

Proceeds when Two orthogonal methods agree with an authenticated reference, adulterant screens are negative, and several documented lots are available.Produces Identity passport, supplier qualification file, import fileRe-screen A new species, plant part, origin or supplier

The problem it solves

A supplier’s certificate of analysis does not establish identity. A supplement manufacturer must verify the identity of every dietary ingredient by at least one appropriate test or examination before use (21 CFR 111.75(a)(1)(i)). Wrong species, wrong plant part, adulteration and lot-to-lot variability all start here.

Technologies evaluated

  • Macroscopy and microscopy of crude material
  • HPTLC fingerprint against authenticated reference material (USP ⟨203⟩; see also ⟨563⟩)
  • HPLC or LC-MS marker profile, and targeted tests for known adulterants
  • DNA barcoding of crude material, through partners
  • Stable isotope ratios, where a synthetic substitute copies the natural profile
  • Supplier audit and verification of certificates against independent results

How alternatives are selected

Methods are combined so that each is blind to something the others see. Processing removes visual and DNA evidence, so extracts depend on chemistry, and DNA methods are used together with chemical methods. Two orthogonal methods agreeing with an authenticated reference would be EUTECNIQ’s internal standard; the rule requires at least one.

What is measured

Identity on several lots by independent methods; the lot-to-lot spread of a few marker attributes; screens for known adulterants and gross contamination; the completeness of origin, harvest and processing records. In one published set of 27 curcuminoid samples, HPLC could not tell synthetic from natural material, and isotope ratios could.

What it produces

An ingredient identity passport; a supplier qualification file with approved specifications; and, for imported material, an import file with permits, prior notices, foreign supplier verification records and access agreements.

Commercial value

Specification, identity and quality-control rules accounted for about half of FDA’s Part 111 citations each year, FY2019–FY2025. A qualified source with an identity passport answers the first questions a buyer or an inspector asks, and secures supply before money goes into process work.

Progress when

Two orthogonal methods agree with an authenticated reference, adulterant screens are negative, and several documented lots are available.

Repeat when

A new supplier, origin or plant part is proposed, or stage 3 traces variability to the raw material. Either also re-runs the feasibility screen.

Stop when

The species or plant part is wrong, an adulterant is found, no authenticated reference exists, the supplier cannot be audited, or a required permit or access agreement is missing.

Sources: 21 CFR Part 111; USP general chapters; Raclariu et al. 2018; Perini et al. 2023; FDA inspection observations, FY2019–FY2025; 21 CFR Part 1, Subpart L; CITES; Nagoya Protocol.

3Extract, separate and optimize

Which process gets the actives out at a defined composition, with an acceptable residue and cost?

Proceeds when The process gives the target composition repeatably at laboratory scale, the mass balance closes and the residue fits the category.Produces Process description, laboratory design space, closed mass balanceRe-screen A new solvent, concentration or purification step

The problem it solves

Yield, purity and recovery are three different numbers tied by one mass balance: yield × purity = recovery × the target’s content in the feed. A process tuned for yield can dilute the target. A laboratory yield is also not a plant cost: solvent-to-feed ratio, the energy to recover solvent, cycle time, downstream purification and the solvent’s fire class decide the cost per kilogram.

Technologies evaluated

  • Maceration and percolation; ultrasound- and microwave-assisted extraction; pressurized liquids
  • Supercritical CO₂, with or without a co-solvent; subcritical water
  • Purification by adsorbent resins, membranes, liquid–liquid partition, preparative and countercurrent chromatography, and molecular distillation

How alternatives are selected

The molecule (polarity, heat sensitivity), the residue the category tolerates and the intended scale narrow the methods first. Water and CO₂ are the reference solvents; FDA affirms CO₂ as GRAS with no limit beyond good manufacturing practice. Designed experiments then map solvent, temperature, ratio and particle size against yield, purity and solvent use. Where these goals conflict, the set of best compromises (a Pareto front) is compared with the specification and the cost target.

What is measured

Extract yield; recovery and purity of the target constituents; degradation products; residual solvent against its ICH Q3C class; solvent-to-feed ratio and solvent recovered; closure of the mass balance.

What it produces

A process description with set points and ranges, a laboratory design space, a closed mass balance and extract lots for characterization at stage 4.

Commercial value

A process that holds composition can be transferred or licensed. Processes can be patent-eligible, while a naturally occurring constituent is not eligible merely because it has been isolated. Solvent recovery usually sizes the plant: the illustrative ethanol train on the process engineering page charges 8 kg of solvent per kilogram of herb.

Progress when

The process gives the target composition repeatably at laboratory scale, the mass balance closes and the residue fits the category.

Repeat when

Variability traced to the raw material returns the program to stage 2; a specification that stage 4 cannot meet, or attributes that drift at stage 7, return it here. A new solvent or concentration step can raise the question whether the extract is a new dietary ingredient, so it re-runs the screen.

Stop when

The content cannot be held within a defined range, the solvent or its residue is unacceptable for the category, or the projected cost of goods exceeds what the market supports.

Sources: ICH Q3C(R9); 21 CFR 184.1240; Association for Molecular Pathology v. Myriad Genetics (2013); FDA revised draft NDI guidance (2016). The mass balance is an identity; the solvent charge is an illustrative input, not plant data.

4Characterize and standardize

What is in the material, how much does it vary, and can every specification be measured reliably?

Proceeds when Every attribute has a fit-for-purpose method, composition falls in a range that can be justified, and contaminants are below the proposed limits.Produces Specification with reasons for each limit, validated methods, certificate-of-analysis format

The problem it solves

An extract can contain hundreds of compounds, and one species can carry different chemistries: Thymus vulgaris alone has six chemotypes. Climate, harvest and drying shift the profile further. A specification has to be built from lot data, every limit needs a method shown to be fit for purpose, and a targeted method finds only what it looks for.

Technologies evaluated

  • UHPLC with diode-array detection; LC-MS/MS; high-resolution LC-MS for non-targeted screening
  • HPTLC and chromatographic fingerprints compared by chemometrics (statistics that compare whole profiles)
  • GC-MS; ICP-MS for elements; compendial microbiology; NMR through partners

How alternatives are selected

Each attribute gets the method that answers its question: targeted assays for named markers and contaminants, non-targeted screening for adulterants and unknowns. The extract type decides what is controlled; the European Medicines Agency distinguishes standardized, quantified and other extracts. Markers are chosen for control, whether or not they cause any effect.

What is measured

Marker and active content; fingerprint similarity to reference lots; elemental impurities, pesticide residues, residual solvents, mycotoxins and microbial counts; moisture and particle size; the spread between lots.

What it produces

A specification with a reason for each limit, methods validated under ICH Q2(R2) with their reports, a certificate-of-analysis format and a characterization package. For supplements the legal test is a scientifically valid method (21 CFR 111.75(h)(1)).

Commercial value

The specification and its certificate of analysis are what a buyer qualifies and what an inspector reads first. Lot-to-lot consistency, shown with data, is the basis of a standardized ingredient that can carry its own name.

Progress when

Every attribute has a fit-for-purpose method, composition falls in a range that can be justified, and contaminants are below the proposed limits.

Repeat when

Marker variability is too wide to standardize: the program returns to stage 3 for the process or stage 2 for the source. A constituent of concern re-opens the safety assessment of stage 6.

Stop when

A contaminant exceeds its limit with no practical removal step, no fit-for-purpose method exists for a critical attribute, or an adulterant or unexplained major constituent appears.

Sources: Thompson et al. 2003; EMA reflection paper on extract types (2010); EMA reflection paper on markers (2008); ICH Q2(R2), FDA final guidance (2024); 21 CFR Part 111.

5Engineer delivery

Which barrier limits the active, and which carrier addresses it in the intended format?

Proceeds when The prototype meets its physical and chemical stability targets, and a stated mechanism links the carrier to the identified barrier.Produces Formulation prototype, delivery technology dossierRe-screen A new carrier, particle size or dosage form

The problem it solves

An active has to dissolve, survive storage and digestion, and cross the gut wall before it reaches the blood. Each step fails for a different physical reason, so the barrier is identified before a carrier is chosen. Higher solubility or dispersibility does not by itself mean higher absorption.

Technologies evaluated

  • Lipid-based and self-emulsifying systems, classed with the lipid formulation classification system
  • Nanoemulsions; phospholipid complexes; cyclodextrin inclusion complexes
  • Amorphous solid dispersions; encapsulation; spray drying and freeze-drying to stable powders

How alternatives are selected

A barrier diagnosis comes first: solubility and partitioning, chemical stability and the likely absorption limit. Carrier families are then measured against limits fixed in advance, using only components lawful in the target category. If absorption is not limited by solubility or dissolution, a carrier would add cost without benefit, and none is added.

What is measured

Solubility and partitioning; droplet or particle size by dynamic light scattering (ISO 22412) and laser diffraction (ISO 13320); surface charge; encapsulation efficiency; dissolution (USP ⟨2040⟩); in vitro digestion with the INFOGEST protocol as a bioaccessibility screen; physical and chemical stability over time.

What it produces

A formulation prototype and a delivery technology dossier that states the mechanism, the measurements and what they do not show. Nanoemulsion stability is not demonstrated bioavailability, and in vitro bioaccessibility is not systemic exposure.

Commercial value

The carrier sets the format, the serving size and the evidence a product needs. A delivery system that is measured, specified and protectable can be licensed across products; its value rests on the human data of stage 6.

Progress when

The prototype meets its physical and chemical stability targets, and a stated mechanism links the carrier to the identified barrier.

Repeat when

The active degrades in the format (back to stage 3 or 4), or stage 6 finds that the format changes exposure or the safety case. A new form re-runs the screen: for a nanoscale form, FDA states that data on the conventional form alone are unlikely to address its safety.

Stop when

Absorption is not limited by solubility or dissolution, excipient levels are unsuitable for the category or dose, the system is physically or chemically unstable, or it cannot be scaled.

Sources: Pouton 2000 and 2006; ISO 22412; ISO 13320; USP ⟨2040⟩; Brodkorb et al. 2019 (INFOGEST); FDA NDI guidance (October 2026).

6Establish safety and performance evidence

Is the ingredient safe at the intended intake, and does the product do what its design is meant to do?

Proceeds when No hazard is known at the intended exposure, EDI/ADI is 1 or less, and the performance target set at stage 5 is met by the kind of evidence the intended claim needs.Produces Safety and exposure assessment, study reports, stability dataRe-screen A new population, dose or claim

The problem it solves

Safety is judged at the intended exposure, and the evidence worth producing depends on the route. No test battery is prescribed for a new dietary ingredient. FDA’s NDI guidance recommends calculating the acceptable daily intake (ADI) as the NOAEL, the highest dose without an adverse effect, divided by a safety factor. An estimated daily intake (EDI) at or below the ADI supports safety.

Technologies evaluated

  • Exposure estimate from the intended use; history-of-use and literature review
  • In vitro screens; studies to OECD guidelines at GLP partner laboratories (21 CFR Part 58)
  • NOAEL or benchmark dose; the threshold of toxicological concern for minor constituents
  • Enzyme and transporter interaction screens
  • Stability studies at ICH Q1A(R2) storage conditions, as good practice
  • Human pharmacokinetic studies with clinical research organizations, under IRB review (21 CFR Parts 50 and 56)

How alternatives are selected

Studies are chosen for each ingredient from its known hazards, prior human use, intended intake and regulatory route, cheapest decisive studies first. Definitive studies would go to GLP laboratories so the data could also support a later food or drug filing. A study designed to test whether a product can diagnose, cure, mitigate, treat or prevent a disease needs an IND (21 CFR Part 312).

What is measured

Estimated daily intake; NOAEL and the resulting ADI; genotoxicity; interaction signals; stability-indicating attributes over time; and, where justified, exposure in people (blood levels over time) against the plain extract.

What it produces

A safety and exposure assessment with the intake limit, study reports where studies were run, stability data and, where a notification is needed, a draft NDI notification for the client or its counsel. Stability data support a shelf life; they are not a validated shelf life (what an NDI acknowledgment means).

Commercial value

Evidence is the part of a product a competitor cannot copy from its label. It is also the largest cost: in EU contract-laboratory quotes from 2010 to 2018, a genotoxicity battery with a 90-day study cost about €140,000, which is why the screen prices the evidence before any study is placed.

Progress when

No hazard is known at the intended exposure, EDI/ADI is 1 or less, and the performance target set at stage 5 is met by the kind of evidence the intended claim needs.

Repeat when

A format that changes exposure or the safety case returns to stage 5; a constituent of concern that a specification can control returns to stage 4. A new population or claim re-runs the screen. FDA’s NDI guidance recommends reproductive and developmental data when a product is intended for use in pregnancy, lactation or young children.

Stop when

Genotoxicity appears, the NOAEL is low relative to intake, a clinically relevant interaction is found, or the testing would cost more than the commercial case can carry.

Sources: FDA NDI guidance (October 2026), sections VII and IX; 21 CFR 190.6; 21 CFR Part 58; 21 CFR Parts 50 and 56; 21 CFR Part 312; EFSA benchmark dose guidance (2022); EFSA TTC guidance (2019); ICH Q1A(R2); Meigs et al. 2018, Table 3 (third-party estimate).

7Scale, validate and transfer

Does a larger process make on-specification material with its critical parameters known, and can another site repeat it?

Proceeds when Consecutive pilot batches meet the specification under a written control strategy, and every release attribute has a validated method.Produces Process development and transfer package, control strategyRe-screen A change of process, scale or site

The problem it solves

The laboratory hides physics that changes at plant scale: slower heating, coarser particles, longer mixing and the cost of recovering solvent. A larger, geometrically similar tank cannot hold power per volume, tip speed and Reynolds number constant at once, so each unit operation needs its own scale-up basis.

Technologies evaluated

  • Pilot extraction, evaporation, solvent recovery and pilot drying
  • Mass and energy balances; designed experiments; dimensionless scale-up rules
  • Quality by design: critical quality attributes (CQAs) linked to critical process parameters (CPPs), with risk ranking
  • Process analytical technology, such as near-infrared monitoring of an extraction
  • Transfer of analytical procedures (USP ⟨1224⟩), and comparability against criteria set in advance

How alternatives are selected

A scale-up basis is chosen for each unit operation from published practice, then tested in pilot runs. In one published spray-drying scale-up, matching the atomized droplet size still left production trials necessary, because mixing and residence time differed. The control strategy starts with extensive end-product testing and moves toward process control only as data accumulate.

What is measured

CQAs against CPPs; yield and purity together; residual solvent; heat history; batch-to-batch consistency; closure of the mass and energy balances.

What it produces

A process development and transfer package: the process with its ranges, the CQA–CPP map, specifications with validated methods, a risk assessment of equipment and scale gaps, and the records a receiving supplement site keeps under 21 CFR Part 111. After any change, a comparability package.

Commercial value

A process another qualified site can repeat is what can be licensed, placed with a contract manufacturer or run for supply. Laboratory feasibility is not commercial demonstration, and this stage is where the difference is paid for.

Progress when

Consecutive pilot batches meet the specification under a written control strategy, and every release attribute has a validated method.

Repeat when

Quality attributes drift with scale (back to stage 3), or the format fails in processing (back to stage 5). A change of process or site is compared against criteria set in advance and re-runs the screen.

Stop when

Solvent or energy use is unsafe or uneconomic, the cost of goods exceeds what the market supports, or no qualified manufacturing capacity is available.

Sources: ICH Q8(R2); ICH Q9(R1); ICH Q10; ICH Q5E (written for biotechnological products; its logic applied here); USP ⟨1224⟩ (Pappa); Thybo et al. 2008; Pan et al. 2015; Yu et al. 2014; 21 CFR Part 111.

8Commercialize, license, supply or pursue drug development

Which route turns the evidence into value: a client program, a license, supply or a partnered drug program?

Proceeds when A customer or partner commits, ownership and data terms are agreed before work starts, and counsel has reviewed freedom to operate.Produces IP and commercialization assessment, supply and quality agreements, or a partnering fileRe-screen New claims, a new market or a drug use

The problem it solves

Evidence earns nothing until someone buys, licenses or develops it, and the law constrains the route. Claims in labeling and marketing establish intended use. If an article is approved as a drug, or authorized for investigation as one with substantial clinical investigations made public, before it is marketed as a supplement or food, it cannot later be sold as a supplement (21 U.S.C. 321(ff)(3)(B)); so the route is confirmed before any public step.

Tools evaluated

  • Prior-art and patent landscaping; ownership mapping under written agreements
  • Freedom-to-operate review by patent counsel
  • A commercial model and a supply plan
  • Market-access assessment by category and country

How alternatives are selected

Each route has its own gate. A client program fits when the client owns the result under contract. A license fits when a composition, process, formulation or method of use is protectable, and supply when a specified ingredient can be made at a margin. Drug development fits only on a strong signal and only with a partner that has drug development capacity.

What is measured

The defensible difference from existing products; freedom-to-operate findings; supply security at scale; margin; and a customer’s or partner’s commitment.

What it produces

An IP and commercialization assessment; a commercial specification and certificate-of-analysis format; supply and quality agreements with a specification exhibit and change control; a technology-transfer file; or a partnering file for a drug candidate.

Commercial value

Fees come first, then ingredients, licenses and supply. Drug candidates come last, and only through partners. FDA lists four botanical products approved as drugs under the NDA and BLA pathways. Five-year new-chemical-entity exclusivity attaches only on drug approval; supplements have no data exclusivity.

Progress when

A customer or partner commits, ownership and data terms are agreed before work starts, and counsel has reviewed freedom to operate.

Repeat when

A claim needs more evidence (back to stage 6), or a new claim, market or drug use changes the intended use and re-runs the screen.

Stop when

There is no defensible difference, freedom to operate is blocked, supply cannot be secured or margins do not work. A drug program stops when no partner exists or the supplement channel is already the chosen first use.

Sources: 21 U.S.C. 321(g)(1) and (ff)(3)(B); 21 CFR 101.93; Myriad (2013); FDA CDER, “What is a Botanical Drug?” (updated September 3, 2026); FDA authors, Ther Innov Regul Sci 2025; FDA, patents and exclusivity FAQ. Routes and gate criteria are EUTECNIQ proposals.

See the three ways in, the fifteen detailed steps within the stages and the four named gates

02 · The sciences inside the stages

Seven sciences, and the ingredient they lead to, each shown with its governing equation or rule

The stages say what must be decided; these say how. Each panel states its basis: an equation, a EUTECNIQ calculation, published data analyzed here, a model estimate or a proposal.

01 Physics-informed botanical intelligence

y(x) = fphys(x; θ, h(x)),  0 ≤ y ≤ Y∞

00.5100.10.20.3Dimensionless time Dt / r²Y / Y∞training rangephysics + learned residual: above Y∞clipped to the boundphysics alone
00.5100.10.20.3Dimensionless time Dt / r²Y / Y∞training rangephysics + residual: above Y∞clipped to the boundphysics alone

Learned models that keep their physics and their bounds: a residual alone can leave the feasible states, so constraints are enforced and violations counted.

Illustrative correction Scientific Intelligence

02 Molecular modeling and thermodynamics

ln γi = ni Σσ pi(σ) [ln ΓS(σ) − ln Γi(σ)] + ln γiSG

01530−0.02−0.010+0.01+0.02Screening charge σ, e/ŲShare of surface per bin, %WaterEthanoln-Hexane
01530−0.02−0.010+0.01+0.02Screening charge σ, e/ŲShare of surface per bin, %WaterEthanoln-Hexane

Solvents and co-formers screened from each molecule's surface-charge profile (COSMO-RS family), before any material is bought.

Computed by EUTECNIQ Quantum chemistry and σ-profiles

03 Precision extraction and separation

Y/Y∞ = 1 − (6/π²) Σn n−2 exp(−n²π²Dt/r²)

00.5100.050.10.150.20.25Time, in units of r₀² / DY / Y∞90% of Y∞ at 0.046 (r₀ / 2) and 0.183 (r₀)radius r₀ / 2radius r₀
00.5100.050.10.150.20.25Time, in units of r₀² / DY / Y∞90% of Y∞ at 0.046 (r₀ / 2) and 0.183 (r₀)radius r₀ / 2radius r₀

Particle size, time, temperature and solvent set yield and selectivity; diffusion sets how they trade off.

Computed from the equation Extraction and separation

04 SNEDDS and advanced delivery

log S0 = 0.5 − 0.01 (Tm − 25) − log P

10⁻⁴10⁻²110²10⁴Estimated intrinsic solubility in water, µg/mL (log scale)Ursolic acidResveratrolCurcuminPiperineQuercetinCapsaicinCaffeineEGCG
10⁻⁴10⁻²110²10⁴Estimated intrinsic solubility in water, µg/mL (log scale)Ursolic acidResveratrolCurcuminPiperineQuercetinCapsaicinCaffeineEGCG

Many botanical actives dissolve poorly; the estimate says when a carrier such as a self-nanoemulsifying system is worth testing.

Model estimate Delivery systems

05 Characterization and standardization

T² = Σk tk² / λk

06.632651 batches, ordered by T²Hotelling T²95% limit 6.63outside: X6, X5, V2
06.632651 batches, ordered by T²Hotelling T²95% limit 6.63outside: X6, X5, V2

A multivariate fingerprint flags a lot that is unusual against its reference set, for a confirmatory method to explain.

Published data, analyzed here Lot consistency

06 PK, PBPK and safety evidence

Fh = QH / (QH + fu·CLint)

00.511101001000Unbound intrinsic clearance fu·CLint, L/h (log scale)Fh, fraction escaping the liverhalf lost at fu·CLint = QH = 99.5 L/h
00.511101001000Unbound intrinsic clearance fu·CLint, L/h (log scale)Fh, fraction escaping the liverhalf lost at fu·CLint = QH = 99.5 L/h

What reaches the blood, not what is in the capsule: absorption, first pass and clearance decide exposure and its safety margin.

Computed from the equation ADME and pharmacokinetics

07 Process engineering and scale-up

E(θ) = N (Nθ)N−1 e−Nθ / (N − 1)!

00.510123Dimensionless time θ = t / τE(θ)N = 1N = 3N = 10
00.510123Dimensionless time θ = t / τE(θ)N = 1N = 3N = 10

Residence time, heat and mass transfer move from the bench to the plant only if their distributions are designed, not assumed.

Computed from the equation Process engineering

08 Proprietary ingredients

specification + process + exposure data → an ingredient a buyer can verify

Milled rhizome1,000 kgAcetone oleoresinabout 214 kgCurcuminoidsabout 77 kgPublished laboratory yields; plant yields must be measured
Milled rhizome1,000 kgAcetone oleoresinabout 214 kgCurcuminoidsabout 77 kgLaboratory yields; plant yields must be measured

The long-term aim: ingredients EUTECNIQ specifies, documents and owns, paid per kilogram or per license.

Proposal The value path

03 · When something changes

Change one thing and see where the program goes back

A program rarely runs straight through. Choose what changed: the trace shows where that change usually arises, sends the program back to the feasibility screen, and lists what is checked again and the rule behind it.

What changed
Stages 0 to 8 in a column beside the feasibility screen. Highlighted: intake and the stage where the selected change usually arises, with an arrow back to the screen.Feasibility screen0Intake and feasibility screen1Discover and prioritize2Authenticate and qualify the source3Extract, separate and optimize4Characterize and standardize5Engineer delivery6Establish safety and performance evidence7Scale, validate and transfer8Commercialize, license, supply or partner

The material changes: back to the feasibility screen

Usually arises at
Stage 2, authenticate and qualify the source
Checked again
Identity and new-dietary-ingredient status; conservation and access terms; contaminant profile; supply cost and security.
Rule or source
21 CFR 190.6(b)(2) (identity in an NDI notification); CITES; Nagoya Protocol.

Published evidence Proposed capability From the re-screen table in stage 0, where every rule is linked to its source. Rules as of October 2026; not legal advice.

05 · How value would build

Fees first, then owned ingredients, own products and licenses; drug candidates only through partners

The same engine would earn in three ways over time. Each passes its own gate, and success in one does not imply the next.

Near term

Development and testing fees

Stages 0 to 7 offered as full programs or single services, each ending in a document the client receives under contract terms.

Medium term

Owned ingredients, own products, licenses and supply

Ingredients EUTECNIQ designs in their final format, used in its own products and supplied under quality agreements, and processes or formulations licensed where they are protectable. A naturally occurring constituent is not patent-eligible merely because it has been isolated; compositions, processes, formulations and methods of use can be.

Long term

Selected drug candidates, through partners

FDA has approved botanical drugs: it lists four approved under the NDA and BLA pathways, from 2006 to 2023. A candidate would go to a spin-off, licensee or buyer with drug development capacity; EUTECNIQ would not sponsor or manufacture drugs.

Proposed capabilityA business model, not a forecast: no revenue, customer, license or drug program exists. Sources: Myriad (2013); FDA CDER (September 3, 2026); Ther Innov Regul Sci 2025.

How a drug candidate would be carried forward

06 · What a stage result does not prove

Eight results that are easy to overstate

Each stage report would name the claim its data support and the claim they do not.

Stage results that are easy to overstate, and what each does not show
StageWhat the result showsWhat it does not show
1A model predictionA measured result
2A supplier’s certificate of analysisAn identity test
3Extraction yieldPurity
5Higher solubility or dispersibilityHigher absorption
5In vitro bioaccessibilitySystemic bioavailability
6Stability testingA validated shelf life
6An NDI notificationFDA approval
7Laboratory feasibilityCommercial demonstration

See what each proposed document contains, and its limits

07 · Start at intake

Bring a candidate, a material or a process that has stalled

Describe the material, the intended use and the market. The first conversation would be the feasibility screen: whether a lawful route exists and what its evidence would cost.

Sources

Every rule and number on this page traces to these sources

Regulations, guidance, standards and peer-reviewed studies, as cited on the linked EUTECNIQ pages. Each was reviewed on the date given with its citation. Summaries are not legal advice.

Regulation and FDA documents

  1. 21 U.S.C. 321(g)(1) and 321(ff), including (ff)(3)(B). U.S. Code (Cornell LII). law.cornell.edu/uscode/text/21/321
  2. 21 CFR 101.93, certain types of statements for dietary supplements. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93
  3. 21 CFR Part 111, including 111.70 and 111.75. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
  4. 21 CFR 190.6, requirement for premarket notification. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-B/part-190/subpart-B/section-190.6
  5. 21 CFR Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies (58.1, 58.3(e)). eCFR, up to date as of Oct 22, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58
  6. 21 CFR Parts 50 and 56. Protection of human subjects; institutional review boards. eCFR, current to Oct 21, 2026. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50
  7. 21 CFR Part 312, Investigational New Drug Application. eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
  8. 21 CFR Part 1, Subpart L, Foreign Supplier Verification Programs (1.511). eCFR. ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1/subpart-L
  9. FDA warning letter 566205, DK Vitamins, Feb 5, 2019. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dk-vitamins-566205-02052019
  10. Electronic Code of Federal Regulations. 21 CFR 184.1240, Carbon dioxide. Up to date as of October 23, 2026. ecfr.gov/current/title-21/section-184.1240
  11. FDA. NDI Notifications and Related Issues; Identity and Safety Information About the NDI. Guidance for industry, October 2026 (docket FDA-2025-D-6501), sections VII.1 and IX.4–6. fda.gov/media/195770/download
  12. U.S. FDA. Draft Guidance for Industry: Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (revised draft, August 2016; October 2026 revision with Document History). Docket FDA-2011-D-0376. Draft, not for implementation. fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues
  13. FDA CDER. What is a Botanical Drug? Updated Sep 3, 2026. fda.gov/about-fda/cder-offices-and-divisions/what-botanical-drug
  14. FDA. Frequently Asked Questions on Patents and Exclusivity. fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity
  15. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). law.cornell.edu/supremecourt/text/12-398
  16. U.S. Food and Drug Administration. Inspection observations: FY2019–FY2025 spreadsheets, Foods tab (Form 483 observations from FDA's electronic inspection tool), page content current as of December 16, 2025. Summed by 21 CFR Part 111 subpart. Retrieved October 24, 2026. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations

Guidelines, compendia, standards and treaties

  1. FDA. Q2(R2) Validation of Analytical Procedures. Final guidance, March 2024. fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures
  2. ICH Q1A(R2) Stability Testing of New Drug Substances and Products, Step 4 version dated 6 February 2003 (sections 2.1.6 and 2.2.6 testing frequency; 2.1.7.1, 2.1.7.2, 2.2.7.1 storage conditions; 2.2.3 selection of batches). database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
  3. ICH Q8(R2) Pharmaceutical Development, Step 4 version dated August 2009 (glossary; Part II sections 2.3–2.5; Appendices 1 and 2). database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf
  4. ICH Q9(R1) Quality Risk Management, adopted 18 January 2023 (section 3 principles; glossary; Annex I.1 and I.5). database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2022_1219.pdf
  5. ICH Q10 Pharmaceutical Quality System, Step 4 version dated 4 June 2008 (sections 1.6 and 3.2). database.ich.org/sites/default/files/Q10%20Guideline.pdf
  6. ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Step 4, 18 November 2004. database.ich.org/sites/default/files/Q5E%20Guideline.pdf
  7. ICH Q3C(R9) Guideline on impurities: guideline for residual solvents, Step 5. EMA/CHMP/ICH/82260/2006, April 5, 2024 (Tables 1–3; Part VI, 2-MTHF, CPME and TBA). ema.europa.eu/en/documents/scientific-guideline/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf
  8. EMA HMPC. Reflection paper on the level of purification of extracts to be considered as herbal preparations. EMA/HMPC/186645/2008, adopted Sep 16, 2010. ema.europa.eu/en/documents/scientific-guideline/reflection-paper-level-purification-extracts-be-considered-herbal-preparations_en.pdf
  9. EMA Committee on Herbal Medicinal Products. Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products. EMEA/HMPC/253629/2007, 15 July 2008. ema.europa.eu/en/documents/scientific-guideline/reflection-paper-markers-used-quantitative-qualitative-analysis-herbal-medicinal-products_en.pdf
  10. USP Herbal Medicines Compendium. General chapters (⟨561⟩, ⟨563⟩, ⟨565⟩). hmc.usp.org/about/general-chapters
  11. United States Pharmacopeia. ⟨2040⟩ Disintegration and Dissolution of Dietary Supplements. doi.usp.org/USPNF/USPNF_M99970_04_01.html
  12. ISO 22412:2025. Particle size analysis — Dynamic light scattering (DLS). Edition 3, September 2025 (replaces ISO 22412:2017). iso.org/standard/85505.html
  13. ISO 13320:2020. Particle size analysis — Laser diffraction methods. scc-ccn.ca/standardsdb/standards/8168933
  14. Pappa H. USP general chapters on validation, verification and transfer of analytical procedures (<1225>, <1226>, <1224>, <1220>, <1210>). Presentation, Association for Accessible Medicines. accessiblemeds.org/wp-content/uploads/2024/09/Horacio-Pappa-1.pdf
  15. EFSA Scientific Committee; More SJ, Bampidis V, Benford D, et al. Guidance on the use of the benchmark dose approach in risk assessment. EFSA Journal. 2022;20(10):e07584. doi.org/10.2903/j.efsa.2022.7584
  16. EFSA Scientific Committee. Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment. EFSA Journal 2019;17(6):5708. doi.org/10.2903/j.efsa.2019.5708
  17. CITES. What is CITES? cites.org/eng/disc/what.php
  18. Convention on Biological Diversity. About the Nagoya Protocol (adopted Oct 29, 2010; in force Oct 12, 2014). cbd.int/abs/about

Published studies and data

  1. Royal Botanic Gardens, Kew. State of the World's Plants and Fungi 2020. doi.org/10.34885/172
  2. Wang M, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol 2016;34:828–837. doi.org/10.1038/nbt.3597
  3. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3–26. doi.org/10.1016/s0169-409x(00)00129-0
  4. Raclariu AC, Heinrich M, Ichim MC, de Boer H. Benefits and limitations of DNA barcoding and metabarcoding in herbal product authentication. Phytochem Anal. 2018;29(2):123–128. doi.org/10.1002/pca.2732
  5. Perini M, Pianezze S, Ziller L, Larcher R, Pace R. Stable isotope ratio analysis for the authentication of natural antioxidant curcuminoids from Curcuma longa (turmeric). Antioxidants. 2023;12(2):498. Open access (PMC9952763); Table 1 values used in the 02 Ingredient Fingerprint figure (full text read October 31, 2026). doi.org/10.3390/antiox12020498
  6. Thompson JD, Chalchat JC, Michet A, Linhart YB, Ehlers B. Qualitative and quantitative variation in monoterpene co-occurrence and composition in the essential oil of Thymus vulgaris chemotypes. J Chem Ecol. 2003;29(4):859–880. doi.org/10.1023/A:1022927615442
  7. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11 Suppl 2:S93–S98. doi.org/10.1016/S0928-0987(00)00167-6
  8. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–287. doi.org/10.1016/j.ejps.2006.04.016
  9. Brodkorb A, Egger L, Alminger M, et al. INFOGEST static in vitro simulation of gastrointestinal food digestion. Nat Protoc. 2019;14(4):991–1014. doi.org/10.1038/s41596-018-0119-1
  10. Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. Animal testing and its alternatives – the most important omics is economics. ALTEX 2018;35(3):275–305, Table 3. doi.org/10.14573/altex.1807041
  11. Park JK, Lee D, Rui L, Gao X, Furness MS, Wu C. Analysis of regulatory botanical submission profile for cancer management from the U.S. FDA perspectives. Ther Innov Regul Sci. 2025;59(5):1129–1137. doi:10.1007/s43441-025-00786-y pmc.ncbi.nlm.nih.gov/articles/PMC12446141/
  12. Thybo P, Hovgaard L, Lindeløv JS, Brask A, Andersen SK. Scaling up the spray drying process from pilot to production scale using an atomized droplet size criterion. Pharm Res. 2008;25(7):1610–1620. doi.org/10.1007/s11095-008-9565-8
  13. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783 (control strategy levels; CMA definition). doi.org/10.1208/s12248-014-9598-3
  14. Pan X, Li Y, Wu Z, Zhang Q, Zheng Z, Shi X, Qiao Y. A online NIR sensor for the pilot-scale extraction process in Fructus aurantii coupled with single and ensemble methods. Sensors. 2015;15(4):8749–8763. doi.org/10.3390/s150408749

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]